18f fpeb
Small moleculeexperimentalImaging agent
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2009 (NCT00870974)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Also known as
- 18f fpeb
- fluorine-18
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05664763 | Early Phase 1 (Phase 1) | Mar 1, 2023 | National Institute on Drug Abuse (NIDA), Yale University |
| NCT02719951 | Phase 1 | Apr 1, 2016 | University of Toulouse |
| NCT02447640 | Phase 1 | Apr 1, 2015 | Addex Pharma, Johns Hopkins University |
| NCT00870974 | Phase 1 | Mar 1, 2009 | Institute for Neurodegenerative Disorders |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Addex Pharma | For profit | 1 | 0 | 1 | 2015 |
| Institute for Neurodegenerative Disorders | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| National Institute on Drug Abuse (NIDA) | Government | 1 | 0 | 1 | 2023 |
| University of Toulouse | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 2023 |
6 organizations
Page 1 / 1